Back to News
Market Impact: 0.3
Zymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 Million
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cell engager being developed for DLL3-expressing cancers, including small cell lung cancer. The article excerpt provides no financial terms or further details on the agreement.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ZYME0.70
More News
- Jefferies raises Zymeworks stock price target on Roche deal
- Zymeworks licenses cancer drug candidate ZW209 to Roche for $55m
- Roche’s sefaxersen shows 43% proteinuria reduction in IgAN trial
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
- Why is Zymeworks stock surging today?
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage